QC
ITOS

Quantedge Capital’s iTeos Therapeutics ITOS Stock Holding History

Quantedge Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,300
Closed -$295K – 244
2022
Q2 		$295K Buy
14,300
+7,000
+96% +$166K 0.06% 206
2022
Q1 		$235K Buy
+7,300
New +$265K 0.07% 189

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Quantedge Capital's ITOS Position: Q3 2022 in Review

Quantedge Capital sold out of iTeos Therapeutics (ITOS) in Q3 2022, closing a stake of 14,300 shares — an estimated $295K sold.

Quantedge Capital first reported a position in ITOS in Q1 2022 and held it in 2 quarters. The position peaked at $295K in Q2 2022. 143 funds tracked by Wall St. Rank hold ITOS as of Q3 2022.

  • Quantedge Capital reported no remaining iTeos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Quantedge Capital sold 14,300 iTeos Therapeutics shares in Q3 2022, an estimated $295K.
  • Quantedge Capital first reported a position in iTeos Therapeutics in Q1 2022 and held it in 2 quarters.
  • Quantedge Capital's iTeos Therapeutics position peaked at $295K in Q2 2022.
  • 143 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2022.

Based on Quantedge Capital's 13F filing for Q3 2022, filed 10 Nov 2022.